Global Hypoparathyroidism Market to 2030 – Insight, Epidemiology and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypoparathyroidism – Market Insight, Epidemiology and Market Forecast – 2046” report has been added to ResearchAndMarkets.com’s offering.

This report deliver an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Hypoparathyroidism market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hypoparathyroidism market size from 2018 to 2030. The Report also covers current Hypoparathyroidism treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

• The total prevalent population of hypoparathyroidism in the 7MM ranges from 262,542 in 2020 growing at a CAGR of 1.22% during the study period [2018-2030].
• Among the European five countries, Germany had the highest prevalent population of hypoparathyroidism with 28,604 cases, followed by UK and France in 2020. On the other hand, Spain had the lowest prevalent population.
• Japan had 33,276 prevalent cases of hypoparathyroidism in 2020.
• As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.
• According to the analysis, it has been observed that hypoparathyroidism prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool.
• Among the major types of hypoparathyroidism, i.e., Chronic and transient hypoparathyroidism, the former one accounts for a higher number of prevalent cases of hypoparathyroidism.

Scope of the Report

• The report covers the descriptive overview of Hypoparathyroidism, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Hypoparathyroidism epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Hypoparathyroidism is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Hypoparathyroidism market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Hypoparathyroidism market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Hypoparathyroidism market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Hypoparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Hypoparathyroidism. The launch of emerging therapies will significantly impact the Hypoparathyroidism market.
• The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving Hypoparathyroidism.
• To understand the future market competition in the Hypoparathyroidism market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Hypoparathyroidism in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Hypoparathyroidism market.
• To understand the future market competition in the Hypoparathyroidism market.

Companies Mentioned

• Shire (Takeda)
• Ascendis Pharma
• EnteraBio
• Bridgebio/Calcilytix Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/26qs7r

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900